Published in Obesity and Diabetes Week, July 4th, 2005
Analyst Ben Andrew estimated that the company, whose first product, a short-term sensor, is under expedited review by the U.S. Food and Drug Administration (FDA) and could reach the domestic market in second quarter 2006, would generate revenues of $10 million in 2006, $63 million in 2007, and $160 million in 2008, with the company turning profitable in third quarter 2007.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week